林钦

默沙东研发（中国）有限公司药物安全部中国区负责人、总监

Qin Lin has 15 years of experience in the biopharmaceutical industry and is currently the China PV lead at MSD. As internist and cardiologist, she worked in the hospital for three years. With clinical experience she joined in the clinical operation team in CMIC in 2003. During her 5 years at CMIC, she took CRA, CPM and CQM roles to successfully complete several clinical trials. And in 2008, she joined MSD China PV team and is responsible for local PV actives in China. Qin is MSD China PV lead for four years.

张轶菁

拜耳中国药物警戒中国区负责人

Nina STUCCIO

默克实验室医学安全审评和临床试验安全报告副总裁

Nina Stuccio, D.O. has over 15 years of experience in the biopharmaceutical industry and is currently the Global Head of Medical Safety Review and Clinical Trial Safety Reporting at MSD. An internist and nephrologist, with experience as a clinical trial investigator and emergency medicine, she joined the biopharmaceutical industry in 2002 as a Medical Safety Review physician at Janssen/Johnson & Johnson. During her 11 years at Amgen, she provided medical safety support for marketed and late development products as Executive Medical Director, Therapeutic Area Head and Global Safety Officer, General Medicine and Bone prior to leading the successful implementation of a new global safety database. She was then Head of Quality Management for Global Regulatory Affairs and Safety at Amgen prior to joining MSD in 2014 as Global Head of Medical Safety Review and Clinical Trial Safety Reporting. Nina was the Clinical Safety & Risk Management Oncology Therapeutic Area Lead for two years prior to returning to her current role.

任曙光

拜耳医药保健有限公司国际药品安全行政总监

任曙光 (Dawn Ren): 目前职位：拜耳制药，国际药品安全行政总监 (Global Safety Leader) 1995年毕业于哈尔滨医科大学。在妇产科临床工作8年。2005年进入制药行业，先后在默沙东、罗氏及拜耳从事临床试验数据管理和药物警戒工作。至今在药物警戒领域工作11年，其中7年在药品安全风险管理领域（risk management），负责在研药物和上市后药物的获益风险评估 (benefit risk assessment)，发现新药的安全性特性（safety profile）, 对已上市药物进行信号探测 (signal detection)，制定风险管理计划 (risk management plan) 和风险最小化措施 (risk minimization measures)等。